Akari Therapeutics PLC (AKTX)
1.24
-0.23
(-15.65%)
USD |
NASDAQ |
Nov 21, 16:00
1.28
+0.04
(+3.23%)
After-Hours: 20:00
Akari Therapeutics Max Drawdown (5Y): 98.63% for Oct. 31, 2024
Max Drawdown (5Y) Chart
Historical Max Drawdown (5Y) Data
| Date | Value |
|---|---|
| October 31, 2024 | 98.63% |
| September 30, 2024 | 98.63% |
| August 31, 2024 | 98.63% |
| July 31, 2024 | 98.63% |
| June 30, 2024 | 98.63% |
| May 31, 2024 | 98.63% |
| April 30, 2024 | 98.63% |
| March 31, 2024 | 98.19% |
| February 29, 2024 | 98.12% |
| January 31, 2024 | 97.88% |
| December 31, 2023 | 98.57% |
| November 30, 2023 | 98.57% |
| October 31, 2023 | 98.57% |
| September 30, 2023 | 98.57% |
| August 31, 2023 | 98.57% |
| July 31, 2023 | 98.57% |
| June 30, 2023 | 99.00% |
| May 31, 2023 | 99.23% |
| April 30, 2023 | 99.25% |
| March 31, 2023 | 99.28% |
| February 28, 2023 | 99.29% |
| January 31, 2023 | 99.29% |
| December 31, 2022 | 99.29% |
| November 30, 2022 | 99.29% |
| October 31, 2022 | 99.29% |
| Date | Value |
|---|---|
| September 30, 2022 | 99.29% |
| August 31, 2022 | 99.29% |
| July 31, 2022 | 99.29% |
| June 30, 2022 | 99.29% |
| May 31, 2022 | 99.29% |
| April 30, 2022 | 99.29% |
| March 31, 2022 | 99.29% |
| February 28, 2022 | 99.29% |
| January 31, 2022 | 99.29% |
| December 31, 2021 | 99.29% |
| November 30, 2021 | 99.29% |
| October 31, 2021 | 99.29% |
| September 30, 2021 | 99.29% |
| August 31, 2021 | 99.29% |
| July 31, 2021 | 99.29% |
| June 30, 2021 | 99.29% |
| May 31, 2021 | 99.29% |
| April 30, 2021 | 99.29% |
| March 31, 2021 | 99.29% |
| February 28, 2021 | 99.29% |
| January 31, 2021 | 99.29% |
| December 31, 2020 | 99.29% |
| November 30, 2020 | 99.29% |
| October 31, 2020 | 99.29% |
| September 30, 2020 | 99.29% |
Max Drawdown Definition
Max drawdown is an indicator of the risk of a portfolio chosen based on a certain strategy. It measures the largest single drop from peak to bottom in the value of a portfolio before a new peak is achieved.
Max Drawdown (5Y) Range, Past 5 Years
97.88%
Minimum
Jan 2024
99.29%
Maximum
Nov 2019
99.07%
Average
99.29%
Median
Nov 2019
Max Drawdown (5Y) Benchmarks
| DBV Technologies SA | 97.67% |
| Cellectis SA | 97.08% |
| Adaptimmune Therapeutics PLC | 96.57% |
| Biodexa Pharmaceuticals PLC | 100.00% |
| NuCana PLC | -- |
Max Drawdown (5Y) Related Metrics
| Alpha (5Y) | -57.02 |
| Beta (5Y) | 0.9464 |
| Annualized Standard Deviation of Monthly Returns (5Y Lookback) | 81.28% |
| Historical Sharpe Ratio (5Y) | -0.5513 |
| Historical Sortino (5Y) | -1.081 |
| Monthly Value at Risk (VaR) 5% (5Y Lookback) | 36.28% |